Asset Details
Do you wish to reserve the book?
Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections
Do you wish to request the book?
Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections
2006
Overview
Background. Invasive fungal infections are found most frequently in immunosuppressed and critically ill hospitalized patients. Antifungal therapy is often required for long periods. Safety data from the clinical development program of the triazole antifungal agent, posaconazole, were analyzed. Methods. A total of 428 patients with refractory invasive fungal infections (n = 362) or febrile neutropenia (n = 66) received posaconazole in 2 phase II/III open-label clinical trials. Also, 109 of these patients received posaconazole therapy for ⩾6 months. Incidences of treatment-emergent, treatment-related, and serious adverse events and abnormal laboratory parameters were recorded during these studies. Results. Treatment-emergent, treatment-related adverse events were reported in 38% of the overall patient population. The most common treatment-related adverse events were nausea (8%) and vomiting (6%). Treatment-related serious adverse events occurred in 8% of patients. Low rates of treatment-related corrected QT interval and/or QT interval prolongation (1%) and elevation of hepatic enzymes (2%) were reported as adverse events. Treatment-emergent, treatment-related adverse events occurred at similar rates in patients who received posaconazole therapy for <6 months and ⩾6 months. Conclusions. Prolonged posaconazole treatment was associated with a generally favorable safety profile in seriously ill patients with refractory invasive fungal infections. Long-term therapy did not increase the risk of any individual adverse event, and no unique adverse event was observed with longer exposure to posaconazole.
Publisher
The University of Chicago Press,University of Chicago Press,Oxford University Press
Subject
/ Adult
/ Aged
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Antifungal Agents - administration & dosage
/ Antifungal Agents - adverse effects
/ Antifungal Agents - therapeutic use
/ Biological and medical sciences
/ Blood
/ Dosage
/ Dose-Response Relationship, Drug
/ Drug Administration Schedule
/ Female
/ Funding
/ Humans
/ Male
/ Patients
/ Pharmacology. Drug treatments
/ Safety
/ Studies
